ライフサイエンスコーパス: dronabinol

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 nistered Delta(9)-tetrahydrocannabinol (THC; dronabinol).

2 availability and clearer dose-linearity than dronabinol.

3 given 1 dose of placebo or 2.5 mg or 5.0 mg dronabinol.

4 marijuana and -0.04 (CI, -0.20 to 0.14) for dronabinol.

5 s of marijuana (0.00, 1.98, or 3.56% THC) to dronabinol (0, 10, or 20 mg).

6 g/d liquid suspension plus placebo, (2) oral dronabinol 2.5 mg twice a day plus placebo, or (3) both

7 Marijuana (1.98, 3.56%) and dronabinol (20 mg) also increased abuse-related subjecti

8 We compared the effects of dronabinol, a nonselective agonist of the cannabinoid re

9 Dronabinol affected fasting distal MI in patients, regar

10 Dronabinol affected fasting proximal MI in patients with

11 among advanced cancer patients compared with dronabinol alone.

12 lerance did not differ between marijuana and dronabinol, although dronabinol produced analgesia that

13 ent group, 329 received at least one dose of dronabinol and 164 received at least one dose of placebo

14 d Drug Administration-approved cannabinoids (dronabinol and nabilone), which include nausea and vomit

15 In all patients, dronabinol decreased fasting proximal left colonic MI co

16 Compared with placebo, marijuana and dronabinol decreased pain sensitivity (3.56%; 20 mg), in

17 t under controlled conditions, marijuana and dronabinol decreased pain, with dronabinol producing lon

18 agonist, Delta(9)-tetrahydrocannabinol (THC; dronabinol), decreases marijuana withdrawal symptoms, ye

19 We investigated whether oral dronabinol (Delta(9)-tetrahydrocannabinol) might slow th

20 ydrocannabinol marijuana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a

21 Dronabinol did not alter sensation or tone.

22 s safety concerns (114 [35%] patients in the dronabinol group had at least one serious adverse event,

23 145 patients in the dronabinol group had EDSS score progression (0.24 first

24 -PHYS score was 0.62 points (SD 3.29) in the dronabinol group versus 1.03 points (3.74) in the placeb

25 ary end point (marijuana group, 20 patients; dronabinol group, 22 patients; and placebo group, 20 pat

26 Our results show that dronabinol has no overall effect on the progression of m

27 Dronabinol has poor bioavailability, which may contribut

28 ents were randomly assigned (2:1) to receive dronabinol or placebo for 36 months; randomisation was b

29 ared with placebo (overall P = .05; for 5 mg dronabinol, P = .046), decreased fasting distal left col

30 gave an estimated between-group difference (dronabinol-placebo) of -0.9 points (95% CI -2.0 to 0.2).

31 r between marijuana and dronabinol, although dronabinol produced analgesia that was of a longer durat

32 arijuana and dronabinol decreased pain, with dronabinol producing longer-lasting decreases in pain se

33 ients with IBS with diarrhea or alternating, dronabinol reduces fasting colonic motility; FAAH and CN

34 erage changes in viral load in marijuana and dronabinol relative to placebo were -15% (CI, -50% to 34

35 harmaceuticals, Somerset, NJ, USA), Marinol (dronabinol; THC; AbbVie, Inc., North Chicago, IL, USA),

36 te improvement and weight gain compared with dronabinol-treated patients: 75% versus 49% (P =.0001) f

37 of analgesic effects of smoked marijuana and dronabinol under well-controlled conditions using a vali

38 The effects of dronabinol were greatest in patients with IBS with diarr

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。